Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of ACT-1014-6470 in Severe Renal Impairment
NCT04899219Phase 1Completed
- Sponsor
- Idorsia
- Start
- Jun 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ACT-1014-6470 in immune-mediated inflammatory diseases (IMIDs) (2 arms), sponsored by Idorsia. Primary endpoint: Maximum Plasma Concentration up to 6 days. Started Jun 2021; status: completed.
02
Drugs
ACT-1014-6470
03
Conditions
immune-mediated inflammatory diseases (IMIDs)
Beyond the preview
Go deeper on NCT04899219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04899219.